NEW YORK – Trajan Scientific and Medical said Thursday that its Neoteryx subsidiary has secured regulatory authorization in Australia for its remote-use Mitra blood microsampling instrument and sample collection kits under a new manufacturing label.
The IVD registration by Australia's Therapeutic Goods Administration allows use of the firm's Mitra products to collect samples in clinical settings and homes. According to Trajan, samples collected remotely by patients or study participants can be used to support telehealth or boost clinical trial participation.
"The updated regulatory registration of Trajan's Mitra microsampling devices in Australia increases our ability to facilitate personalized, preventive data-based healthcare," Trajan CEO Stephen Tomisich said. "Our Mitra microsampling solutions allow almost anyone to take an analytically viable sample in or out of a clinical setting, anytime, anywhere."
Patients and study participants can use the finger-stick-based instrument to collect samples for shipment to a lab, and the firm said the samples integrate with laboratory analysis workflows. Specimens collected with Mitra kits have been used to detect inflammatory biomarkers, PSA for prostate cancer screening, and antibodies against SARS-CoV-2.